A Japanese flu drug appears to be effective at combatting coronavirus, Chinese studies show

Favipiravir.
(Image credit: KAZUHIRO NOGI/AFP via Getty Images)

Scientists are working around the clock and around the globe to come up with remedies for the novel coronavirus, and, believe it or not, there's been some good news so far.

Chinese medical authorities, for example, have said a Japanese drug called favipiravir, which is normally used to treat new strains of the flu, is "clearly effective" in treating COVID-19 patients, The Guardian reports. And while it would still need government approval for full-scale use, it also has a high degree of safety because it's already been used to treat flu patients. Approval could reportedly happen as early as May, per The Guardian, though that's mostly speculation.

The Chinese studies, which tested 340 COVID-19 patients, have shown patients turned negative for the virus after a median of four days compared to 11 for those who were not administered the drug, and X-rays confirmed lung condition improvements in 91 percent of those who received it versus 62 percent of those who didn't.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up

Of course, favipiravir would be a treatment and not a cure, and Japanese clinical trials have so far found that the drug's effectiveness is not as strong in patients with more severe symptoms.

It's not the only positive development, either. Another study from China found that three macaque monkeys didn't develop a second COVID-19 infection after recovering from their initial exposure, which suggests people may build up immunity after infection, and also provides some hope for research groups looking to use plasma from recovered patients as a treatment for the disease.

Beyond that, companies worldwide are racing to develop faster tests and vaccines, with some clinical trials ready to begin. Read more at The Guardian and The Scientist.

To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.